Abstract 1195P
Background
Low incidence and heterogeneity of NETs complicates the study of epidemiological and clinical pathways in this population. There is an unmet need for large datasets and BD tools to fill this knowledge gap. Our study aimed to describe the demographic and clinical characteristics of patients with NETs in Spain through the application of BD techniques to EHR.
Methods
This was a retrospective, observational study in adult patients with NETs managed in 5 Spanish centers between 01/01/2014 to 31/12/2019. An unstructured search of free text from EHRs was performed by artificial intelligence (AI) techniques based on SAVANA’s EHRead®, an innovative Natural Language Processing and machine learning system. Patients were included when NET was first identified (Index Date) and classified as `Incident´ or `Prevalent´ if the Index Date was within the study window or not, respectively.
Results
A total of 2,939,309 patients were screened by EHRead and 1,256 NETs cases were found: median age 60y (95% CI 59 - 62), 52% female, 41% with gastroenteropancreatic origin, and 44% were categorized as incident (Table). More than 70% of patients presented symptoms prior to diagnosis and >10% had metastases at diagnosis (>70% were non-resectable). Median time from symptom onset to first diagnosis was 0.6 years (95% CI 0.4 - 0.73). The most frequently detected comorbidities were hypertension (66%), diabetes (35%), asthma (22%), and depression (17%). A previous diagnosis of cancer different from NETs was reported in 21% of cases. Uncommon clinical events included brain metastases (1%) and familial history of NETs (1.1%). Table: 1195P
Classification of patients with NETs
FAS (N=1,256) n (%) | Prevalent (N=700) n (%) | Incident (N=556) n (%) | |
Patients with symptoms before Index Date | 366 (29.1) | 0 (0) | 366 (65.8) |
Primary NET site | |||
Gastroenteropancreatic | 412 (41.4) | 235 (42.7) | 177 (39.7) |
Bronchopulmonary | 171 (17.2) | 81 (14.7) | 90 (20.2) |
Other* | 413 (41.5) | 234 (42.5) | 179 (40.1) |
Classified by surgery at Index Date§ | |||
Thyroidectomy | 9 (0.9) | 3 (0.5) | 6 (1.3) |
Adrenalectomy | 1 (0.1) | 0 (0) | 1 (0.2) |
Other classifications | 1 (0.1) | 1 (0.2) | 0 (0) |
Unclassified NETs | 260 (20.7) | 150 (21.4) | 110 (19.8) |
* Paraganglioma, adrenal gland and medullary thyroid carcinomas and pheochromocytomas§ Within +/-6 months of Index Date
Conclusions
BD Techniques should improve generation of large datasets in low incidence neoplasms and help identify uncommon events. NETs diagnosis is delayed about 6m after symptom onset and comorbidities may influence the choice of treatment.
Clinical trial identification
Editorial acknowledgement
Editorial assistance was provided by Content Ed Net (Madrid, Spain)
Legal entity responsible for the study
IPSEN Pharma.
Funding
IPSEN Pharma.
Disclosure
J. Hernando: Financial Interests, Personal, Advisory Board: Eisai, Ipsen, Novartis, AAA, Angelini, Pfizer, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1170P - Survival outcome prediction of primary melanoma tumours from histology images using deep learning
Presenter: Céline Bossard
Session: Poster session 13
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Presenter: Ralf Gutzmer
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13